The market is experiencing strong growth driven by patent expiration of major biologics, increasing demand for affordable therapies, and rising adoption in oncology and autoimmune diseases. Developed regional lead in adoption, while emerging markets are accelerating growth through supportive regulations, expanding healthcare access, and increasing local manufacturing capabilities.
Biosimilar antibodies are highly similar versions of approved monoclonal antibody biologics, designed to match their safety, efficacy, and quality while offering a more affordable treatment option. The U.S. biosimilar antibodies market is growing due to rising healthcare costs and increasing pressure to adopt more affordable biologic alternatives. Expanding regulatory approvals, improving physician confidence, and Greater insurance support are accelerating uptake. Additionally, patent expiration of major monoclonal antibodies and the stronger presence of leading biopharma companies are boosting competition, enhancing accessibility, and driving overall market expansion.
The global biosimilar antibodies market size was estimated at USD 38.6 billion in 2025 and is predicted to increase from USD 44.31 billion in 2026 to approximately USD 153.46 billion by 2035, expanding at a CAGR of 14.8% from 2026 to 2035.
The U.S. biosimilar antibodies market is poised for strong growth, driven by increasing approvals, rising cost pressure on biologics, and growing physician confidence. Future expansion will be supported by improved interchangeability, broader use across therapeutic areas, and stronger payer support, enhancing patient access and fostering competitive pricing.
| Parameter | 2024 | 2025 |
| Total FDA Biosimilar Approval | 19 | 18 |
| Cumulative FDA-Approved Biosimilar | 76 | 82 |
| Denosumab Biosimilar Approvals | 2 | 10+ |
| Ustekinumab Biosimilar Approvals | 5 | 2 |
FDA data shows 2024 recorded 19 biosimilar approvals, with 225 maintaining a similar pace. The increase in cumulative approvals and higher activity in key molecules like denosumab indicate a maturing pipeline, while consistent yearly approvals reflect sustained regulatory support and ongoing expansion of biosimilar antibody availability in the U.S. market.
The monoclonal antibodies (mAbs) segment dominated the U.S. biosimilar antibodies market with a revenue share of 88% in 2025 due to increasing demand for targeted therapies in cancer, autoimmune, and inflammatory diseases. Their high specificity, strong clinical outcomes, and expanding indicators are driving adoption. Additionally, rising biologics and advancements in antibody engineering are further supporting growth and improving patient access to effective treatments.
The oncology segment held a dominant share of 52% in the U.S. biosimilar antibodies market in 2025 due to the high global burden of cancer and the extensive use of monoclonal antibody therapies in its treatment. Strong clinical effectiveness of targeted biologics, increasing adoption of biosimilars to reduce costs, and frequent patent expirations of key oncology drugs are driving growth. Additionally, rising early diagnosis rates and growing healthcare investments further support the segment’s dominant position.
The hospital pharmacies segment led the U.S. biosimilar antibodies market with a share of 64% in 2025 due to the need for controlled handling and administration of biosimilar antibodies, especially in oncology and autoimmune treatments. These therapies often require clinical supervision, proper storage, and monitoring, which hospitals provide. Additionally, bulk procurement systems, established treatment protocols, and higher patient inflow hospitals further support their dominant role in distribution.
The hospitals segment held a dominant share of 68% in the U.S. biosimilar antibodies market in 2025 due to the high volume of patients requiring complex biologic treatments, particularly in oncology and autoimmune diseases. Hospitals provide specialized infrastructure, skilled professionals, and close patient monitoring for safe administration. Additionally, strong procurement systems, established treatment protocols, and physician preference for hospital-based care further reinforce their leading position in the market.
Leading companies in the market include Amgen, Pfizer, Biogen, Sandoz, Coherus BioSciences, Viatris, Samsung Bioepis, and Celltrion. These companies lead through robust biosimilar portfolios of monoclonal antibodies, focusing on oncology and autoimmune diseases, while driving innovation in cost-effective biologics, advanced manufacturing, and expanding access to targeted therapies across the U.S. market.
By Molecular Type
By Application
By Distribution Channel
